TransMedics Group (NASDAQ:TMDX) Stock Price Down 5.2% - Time to Sell?

TransMedics Group, Inc. (NASDAQ:TMDX - Get Free Report)'s share price traded down 5.2% on Friday . The company traded as low as $118.83 and last traded at $118.23. 229,037 shares changed hands during trading, a decline of 83% from the average session volume of 1,364,356 shares. The stock had previously closed at $124.78.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on TMDX. Needham & Company LLC reiterated a "hold" rating on shares of TransMedics Group in a report on Tuesday, June 17th. Piper Sandler reiterated an "overweight" rating and issued a $145.00 target price (up previously from $125.00) on shares of TransMedics Group in a research note on Wednesday, June 4th. Finally, Oppenheimer raised their target price on TransMedics Group from $130.00 to $150.00 and gave the company an "outperform" rating in a report on Tuesday, June 17th. Three analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, TransMedics Group presently has an average rating of "Moderate Buy" and an average target price of $127.33.

TransMedics Group Stock Performance

The company's fifty day simple moving average is $125.49 and its two-hundred day simple moving average is $90.85. The company has a market capitalization of $3.95 billion, a price-to-earnings ratio of 85.94 and a beta of 2.06. The company has a debt-to-equity ratio of 1.92, a quick ratio of 8.32 and a current ratio of 9.10.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported $0.70 EPS for the quarter, topping analysts' consensus estimates of $0.29 by $0.41. The business had revenue of $143.54 million during the quarter, compared to the consensus estimate of $123.39 million. TransMedics Group had a return on equity of 21.88% and a net margin of 10.03%. The company's revenue for the quarter was up 48.2% compared to the same quarter last year. During the same period last year, the firm earned $0.35 earnings per share. Equities research analysts predict that TransMedics Group, Inc. will post 1 earnings per share for the current fiscal year.

Insider Activity at TransMedics Group

In other news, Director Edward M. Basile sold 5,000 shares of TransMedics Group stock in a transaction dated Tuesday, May 27th. The shares were sold at an average price of $126.45, for a total value of $632,250.00. Following the completion of the transaction, the director directly owned 2,866 shares of the company's stock, valued at approximately $362,405.70. The trade was a 63.56% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Anil P. Ranganath sold 686 shares of the company's stock in a transaction on Monday, June 9th. The stock was sold at an average price of $139.80, for a total value of $95,902.80. Following the transaction, the insider owned 13,955 shares of the company's stock, valued at approximately $1,950,909. The trade was a 4.69% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 12,418 shares of company stock valued at $1,512,613. Corporate insiders own 7.00% of the company's stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. NBC Securities Inc. acquired a new position in shares of TransMedics Group during the first quarter worth approximately $25,000. Opal Wealth Advisors LLC bought a new stake in TransMedics Group during the 2nd quarter valued at $26,000. Smartleaf Asset Management LLC boosted its position in TransMedics Group by 44.3% during the 1st quarter. Smartleaf Asset Management LLC now owns 440 shares of the company's stock worth $30,000 after acquiring an additional 135 shares during the period. Atlas Capital Advisors Inc. bought a new position in shares of TransMedics Group in the fourth quarter worth $31,000. Finally, Quarry LP increased its holdings in shares of TransMedics Group by 88.5% during the first quarter. Quarry LP now owns 592 shares of the company's stock valued at $40,000 after purchasing an additional 278 shares during the period. Institutional investors own 99.67% of the company's stock.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.